Abstract:Glucagon has plenty of effects via a specific glucagon receptor(GCGR) like elevating the blood glucose, improving fatty acids metabolism, energy expenditure and increasing lipolysis in adipose tissue. The most important role of glucagon is to regulate the blood glucose, but the emergent possibilities of hyperglycaemia is exist. Glucagon could also slightly activate glucagon-like peptide-1 receptor(GLP-1R), which lead to blood glucose lowering effect. This study aims to erase the likelihood of hyperglycaemia and to remain the inherent catabolic effects through improving GLP-1R activation and deteriorating GCGR activation so as to lower the bodyweight and show diabetes-protective effects. Firstly, twelve cysteine modified GLP-1/GCGR dual agonists were synthesized (1-12). Then, the GLP-1R/GCGR mediated activation and biological activity in normal ICR mice were comprehensively performed. Compounds substituted by cysteine at positions 22, 23 and 25 in glucagon were observed to be better regulators of the body weight and blood glucose. To prolong the half-lives of derivatives, various fatty side chain maleimides were modified to optimal glucagon analogues. Laurate maleimide conjugate 4d was the most potent. Administration of 1000 nmol/kg 4d once every two days for a month normalized adiposity and glucose tolerance in diet-induced obese (DIO) mice. Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were observed. These studies suggest that compound 4d behaves well in lowering body weight and maintaining energy expenditure without a chance of hyperglycaemia, 4d has strong clinical potential as an efficient GLP-1/GCGR agonist in the prevention and treatment of obesity and dyslipidemia. (C) 2017 Elsevier Masson SAS. All rights reserved.

Synthesis and Lipid-Lowering Evaluation of 3-Methyl-1h-purine-2,6-dione Derivatives As Potent and Orally Available Anti-Obesity Agents.

Synthesis and biological evaluation of 3-methyl-5-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives for the treatment of diet-induced obesity.

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Design, synthesis and evaluation of 2-pyrimidinylindole derivatives as anti-obesity agents by regulating lipid metabolism

Synthesis and Biological Evaluation of Novel Bouchardatine Derivatives As Potential Adipogenesis/Lipogenesis Inhibitors for Antiobesity Treatment

Synthesis and Biological Evaluation of Tert-Butyl-5-methylpyrimidin-piperazine Derivatives As Anti-Obesity Agents.

Design, synthesis and structure-activity relationship of novel 2-pyrimidinylindole derivatives as orally available anti-obesity agents

Synthesis and biological evaluation of novel urea- and guanidine-based derivatives for the treatment of obesity-related hepatic steatosis.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Discovery of a Promising Agent IQZ23 for the Treatment of Obesity and Related Metabolic Disorders.

Characterization of in Vivo Metabolites of a Potential Anti-obesity Compound, the 3-Methyl-1h-purine-2,6-dione Derivative C-11, Employing Ultra-High Performance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry

Design, Synthesis and Biological Evaluation of Novel Bouchardatine Analogs As Potential Inhibitors of Adipogenesis/lipogenesis in 3T3-L1 Adipocytes

Lipid Accumulation Inhibitory Activities of Novel Isoxazole-Based Chenodeoxycholic Acids: Design, Synthesis and Preliminary Mechanism Study

Design, Synthesis and Biological Evaluation of Thiazole- and Indole-Based Derivatives for the Treatment of Type II Diabetes

A Novel Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist Exhibits Weight-Lowering and Diabetes-Protective Effects.

Development of Novel N -Acylhydrazone Derivatives with High Anti-obesity Activity and Improved Safety by Exploring the Pharmaceutical Properties of Aldehyde Group

Creation of an Anti-Inflammatory, Leptin-Dependent Anti-Obesity Celastrol Mimic with Better Druggability

Discovery of a Potent 9‐deazaxanthine‐based Agent for the Treatment of Obesity‐Related Non‐alcoholic Fatty Liver Disease

Discovery of a Novel GLP-1/GIP Dual Receptor Agonist CY-5 As Long-Acting Hypoglycemic, Anti-Obesity Agent

Flavonoid derivatives synthesis and anti-diabetic activities

Design, synthesis and biological evaluation of novel oxazole derivatives as potential hypoglycemic agents